Jiaojiao Zhou1, Jing Lu2, Diming Cai3. 1. Division of Ultrasound, West China Hospital of Sichuan University, Chengdu, Sichuan, China. 2254831@qq.com. 2. Division of Nephrology, The Seventh People's Hospital of Chengdu, The Oncology Hospital of Chengdu, Chengdu, Sichuan, China. 3. Division of Ultrasound, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Abstract
PURPOSE: The protective effect of recombinant human erythropoietin (rHuEPO) on kidney transplantation has not been established. Therefore, we conducted a systematic review and meta-analysis to evaluate the potential influence of rHuEPO on transplanted kidneys. MATERIALS AND METHODS: To identify relevant studies, we searched electronic databases (PubMed, Medline, EMBASE, Ovid, the Cochrane Library, and major nephrology journals) from inception until June 15, 2018. Two independent reviewers assessed study quality. The systematic review and meta-analysis were performed with fixed- or random-effects models according to heterogeneity, and results are expressed as risk ratios (RR) or weighted mean differences. RESULTS: Six randomized controlled trials with a total of 435 patients met the inclusion criteria. rHuEPO, compared with placebo, had no statistically significant effect on delayed graft function (RR = 0.89, 95% confidence interval [CI] , 0.73 to 1.07; P = 0.22) and slow graft function (RR = 0.93, 95% CI, 0.60 to 1.43; P = 0.73). The rHuEPO and control groups did not differ in thromboembolic events, mortality, acute rejection, and blood transfusion. A significant difference was found in long-term estimated glomerular filtration rate (RR = 3.65, 95% CI, -4.45 to 11.75; P = 0.003). CONCLUSION: Our findings suggests that rHuEPO has a limited nephroprotective effect in patients undergoing kidney transplantation and does not increase the susceptibility to adverse events.
PURPOSE: The protective effect of recombinant humanerythropoietin (rHuEPO) on kidney transplantation has not been established. Therefore, we conducted a systematic review and meta-analysis to evaluate the potential influence of rHuEPO on transplanted kidneys. MATERIALS AND METHODS: To identify relevant studies, we searched electronic databases (PubMed, Medline, EMBASE, Ovid, the Cochrane Library, and major nephrology journals) from inception until June 15, 2018. Two independent reviewers assessed study quality. The systematic review and meta-analysis were performed with fixed- or random-effects models according to heterogeneity, and results are expressed as risk ratios (RR) or weighted mean differences. RESULTS: Six randomized controlled trials with a total of 435 patients met the inclusion criteria. rHuEPO, compared with placebo, had no statistically significant effect on delayed graft function (RR = 0.89, 95% confidence interval [CI] , 0.73 to 1.07; P = 0.22) and slow graft function (RR = 0.93, 95% CI, 0.60 to 1.43; P = 0.73). The rHuEPO and control groups did not differ in thromboembolic events, mortality, acute rejection, and blood transfusion. A significant difference was found in long-term estimated glomerular filtration rate (RR = 3.65, 95% CI, -4.45 to 11.75; P = 0.003). CONCLUSION: Our findings suggests that rHuEPO has a limited nephroprotective effect in patients undergoing kidney transplantation and does not increase the susceptibility to adverse events.
Authors: Joyce Baard; Shahrokh F Shariat; Morgan Roupret; Takashi Yoshida; Alberto Saita; Iliya Saltirov; Javier Revilla Burgos; Orcun Celik; Jean de la Rosette; Pilar Laguna Journal: World J Urol Date: 2022-10-05 Impact factor: 3.661
Authors: Walaa H El-Maadawy; Marwa Hassan; Ehab Hafiz; Mohamed H Badawy; Samir Eldahshan; AbdulRahman AbuSeada; Maha A M El-Shazly; Mosad A Ghareeb Journal: Sci Rep Date: 2022-04-14 Impact factor: 4.996